ReviewCurrent allergy and asthma reports2016
Hymenoptera Allergy and Mast Cell Activation Syndromes.
Review in Current allergy and asthma reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 68 citations in OpenAlex.
- The REMA Score Revisited: An Optimized Algorithm for Early Prediction of Clonal Mast Cell Disease.Allergy · 2026Article
- Immunosenescence and Allergy: Molecular and Cellular Links Between Inflammaging, Neuro-Immune Aging, and Response to Biologic Therapies.International journal of molecular sciences · 2026Review
- French guidelines for the management of nonadvanced mastocytosis in adults.Orphanet journal of rare diseases · 2025Article
- Hymenoptera venom allergy in children.Italian journal of pediatrics · 2024Review
- High burden of clonal mast cell disorders and hereditary α-tryptasemia in patients who need Hymenoptera venom immunotherapy.Allergy · 2024Article
- Challenges in Drug and Hymenoptera Venom Hypersensitivity Diagnosis and Management in Mastocytosis.Diagnostics (Basel, Switzerland) · 2024Review
- Case Report: Multidisciplinary management of a patient with indolent systemic mastocytosis and refractory symptoms.Frontiers in allergy · 2024Article
- Cluster-Analytic Identification of Clinically Meaningful Subtypes in MCAS: The Relevance of Heat and Cold.Digestive diseases and sciences · 2023Article
- Diagnosis ofBiomedicines · 2022Review
- Review
- The Number of MRGPRX2-Expressing Cells Is Increased in Skin Lesions of Patients With Indolent Systemic Mastocytosis, But Is Not Linked to Symptom Severity.Frontiers in immunology · 2022Article
- Treatment of Indolent and Advanced Systemic Mastocytosis.Mediterranean journal of hematology and infectious diseases · 2022Review
- Article
- Mastocytosis and Mast Cell Activation Disorders: Clearing the Air.International journal of molecular sciences · 2021Review
- Mechanisms Governing Anaphylaxis: Inflammatory Cells, Mediators, Endothelial Gap Junctions and Beyond.International journal of molecular sciences · 2021Review
- Mast Cells in the Skin: Defenders of Integrity or Offenders in Inflammation?International journal of molecular sciences · 2021Review
- Current practices in diagnosis of Hymenoptera venom allergy in Poland.Postepy dermatologii i alergologii · 2021Article
- Systemic Mastocytosis: Multidisciplinary Approach.Mediterranean journal of hematology and infectious diseases · 2021Review
- Diagnosis, Classification and Management of Mast Cell Activation Syndromes (MCAS) in the Era of Personalized Medicine.International journal of molecular sciences · 2020Review
- Microarray-Based Detection of Allergen-Reactive IgE in Patients with Mastocytosis.The journal of allergy and clinical immunology. In practice · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mast cell activation syndrome (MCAS) can be diagnosed in patients with recurrent, severe symptoms from mast cell (MC)-derived mediators, which are transiently increased in serum and are attenuated by mediator-targeting drugs. When KIT-mutated, clonal MC are detected in these patients, a diagnosis of primary MCAS can be made. Severe systemic reactions to hymenoptera venom (HV) represent the most common form of anaphylaxis in patients with mastocytosis. Patients with primary MCAS and HV anaphylaxis are predominantly males and do not have skin lesions in the majority of cases, and anaphylaxis is characterized by hypotension and syncope in the absence of urticaria and angioedema. A normal value of tryptase (≤11.4 ng/ml) in these patients does not exclude a diagnosis of mastocytosis. Patients with primary MCAS and HV anaphylaxis have to undergo lifelong venom immunotherapy, in order to prevent further potentially fatal severe reactions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.